BR MG01
Alternative Names: BR-MG01Latest Information Update: 25 Aug 2023
At a glance
- Originator BlueRock Therapeutics
- Class Gene therapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements; Glial cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lysosomal storage diseases; Neurodegenerative disorders
Most Recent Events
- 20 Jul 2023 Preclinical trials in Lysosomal storage diseases in USA (Parenteral)
- 20 Jul 2023 Preclinical trials in Neurodegenerative disorders in USA (Parenteral) (BlueRock Therapeutics pipeline, July 2023 )